LobbyingOvid Therapeutics lobbying by quarter
Ovid Therapeutics OVID's latest lobbying report covers Q1 2023, at $20K. Its first report covers Q4 2022; the issues it reports most are Pharmacy.
Ovid TherapeuticsOVID
- Latest quarter
- No record
- Q2 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q2 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $20K | 1 |
| Q1 2023 | $20K | 1 |
| Q2 2023 | $0 | 0 |
| Q3 2023 | $0 | 0 |
| Q4 2023 | $0 | 0 |
| Q1 2024 | $0 | 0 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
Policy issues the reports name
- Pharmacy1 reports
A report that names several issues counts once for each.
Who was lobbied
- HOUSE OF REPRESENTATIVES1 reports
- SENATE1 reports
Firms it paid
| Firm | ||
|---|---|---|
| The KPM Group DC | $40K | 2 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 23/04/20for Q1 2023 | The KPM Group DC | $20K |
| 23/01/19for Q4 2022 | The KPM Group DC | $20K |